Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance
Read More